Details of the Drug

General Information of Drug (ID: DMRJLAT)

Drug Name
Osimertinib
Synonyms Tagrisso
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Melanoma 2C30 Phase 3 [2]
ATC Code
L01EB04: Osimertinib
L01EB: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 499.6
Logarithm of the Partition Coefficient (xlogp) 3.7
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 6 h []
Clearance
The oral clearance of drug is 14.2 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 48 hours [3]
Metabolism
The drug is metabolized via the CYP3A and dealkylation []
Vd
The volume of distribution (Vd) of drug is 986 L []
Chemical Identifiers
Formula
C28H33N7O2
IUPAC Name
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
Canonical SMILES
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChI
InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
InChIKey
DUYJMQONPNNFPI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
71496458
ChEBI ID
CHEBI:90943
CAS Number
1421373-65-0
UNII
3C06JJ0Z2O
DrugBank ID
DB09330
TTD ID
D0O8GK
VARIDT ID
DR00655
ACDINA ID
D00495
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
EGFR T790M mutant (EGFR T790M) TTZ04AF EGFR_HUMAN Inhibitor [4]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [5]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [6]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [7]
Catalase (CAT) OTHEBX9R CATA_HUMAN Drug Response [7]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Gene/Protein Processing [7]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [8]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Post-Translational Modifications [8]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Protein Interaction/Cellular Processes [9]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Post-Translational Modifications [6]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 8.30E-26 0.06 0.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 1.238 5.6339 -1.8638 8.5762
EW-12 GDSC2 0.2935 2.273 -0.9021 4.9133
ES8 GDSC2 0.2969 2.7545 -1.1383 6.3878
EW-3 GDSC2 0.3017 2.6414 -1.0784 5.9991
ES1 GDSC2 0.3768 2.9818 -1.1897 6.5039
U-CH2 GDSC2 0.5402 6.0419 -2.5834 14.4768
EW-7 GDSC2 0.5904 3.5084 -1.2898 6.597
ES6 GDSC2 0.6028 3.6938 -1.3718 7.0746
CAL-72 GDSC2 0.7853 5.063 -1.9106 9.9185
SJSA-1 GDSC2 0.8038 4.9122 -1.8227 9.3443
CADO-ES1 GDSC2 0.8975 3.4819 -1.0617 4.5159
EW-1 GDSC2 0.9546 3.6881 -1.122 4.7589
NOS-1 [Human HNSCC] GDSC2 0.9667 4.8554 -1.6768 8.0777
A-673 GDSC2 1.0018 3.6186 -1.058 4.2832
EW-18 GDSC2 1.0019 3.5034 -1.0037 3.9635
G-292 clone A141B1 GDSC2 1.0065 3.6052 -1.0487 4.2193
EW-22 GDSC2 1.0161 3.2253 -0.865 3.1317
HuO9 GDSC2 1.147 3.5252 -0.9232 3.2315
NY GDSC2 1.1629 5.201 -1.7067 7.8137
EW-24 GDSC2 1.201 3.7813 -1.0082 3.6197
EW-11 GDSC2 1.3111 9.1412 -3.5293 17.3316
SK-PN-DW GDSC2 1.3719 3.4856 -0.7759 2.0785
ES5 GDSC2 1.3991 9.8676 -3.8219 18.4465
H-EMC-SS GDSC2 1.448 5.0143 -1.4276 5.5793
HOS GDSC2 1.4951 6.756 -2.2277 10.1058
U2OS GDSC2 1.5091 6.1898 -1.9455 8.4622
CHSA0011 GDSC2 1.5196 6.376 -2.0277 8.9125
CAL-78 GDSC2 1.5854 3.3205 -0.5987 0.9986
MG-63 GDSC2 1.613 3.3573 -0.6007 0.9815
ES4 GDSC2 1.6416 8.1291 -2.791 12.8553
CHSA0108 GDSC2 1.6926 4.302 -0.958 2.5672
EW-16 GDSC2 1.71 9.8167 -3.5664 16.5368
MHH-ES-1 GDSC2 1.8223 5.6093 -1.4707 5.1383
SK-ES-1 GDSC2 1.9263 3.9414 -0.6901 1.0626
SaOS-2 GDSC2 1.9406 4.4833 -0.9056 1.99
TC-71 GDSC2 1.9902 3.7197 -0.5764 0.6063
ES7 GDSC2 2.1499 4.978 -1.0079 2.2259
HuO-3N1 GDSC2 2.2137 4.5592 -0.805 1.2685
EW-13 GDSC2 2.5033 4.7088 -0.7364 0.7993
CHSA8926 GDSC2 2.7188 4.4588 -0.5616 0.2525
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 162 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC2 1.5228 3.9095 -0.879 2.398
SU-DHL-1 GDSC2 -5.8094 299.6801 -154.7083 50.1487
HT GDSC2 -4.7358 271.9118 -139.9223 49.951
SUP-B8 GDSC2 -1.5456 1.6762 -2.321 19.8623
SR GDSC2 -1.1574 0.6021 -1.4666 13.3146
MC116 GDSC2 -1.087 22.2003 -12.0185 41.0718
TUR GDSC2 -0.603 6.5611 -3.7957 24.0429
MV4-11 GDSC2 -0.6025 1.3799 -1.2394 9.7945
MOLM-13 GDSC2 -0.4345 1.3115 -1.0456 8.0019
GDM-1 GDSC2 -0.4148 2.1266 -1.4261 10.3092
CTB-1 GDSC2 -0.4139 28.035 -14.3639 41.372
SU-DHL-5 GDSC2 -0.2927 4.7709 -2.6336 17.2003
DEL GDSC2 -0.1353 1.881 -1.0555 7.0867
EoL-1 GDSC2 0.0204 5.1269 -2.5465 15.7484
THP-1 GDSC2 0.0293 2.4574 -1.2044 7.5396
SKM-1 GDSC2 0.0476 4.466 -2.1935 13.6118
Kasumi-1 GDSC2 0.1247 3.0121 -1.4034 8.5236
RPMI-8402 GDSC2 0.162 2.723 -1.229 7.3208
WSU-DLCL2 GDSC2 0.2338 2.2748 -0.9489 5.3618
MLMA GDSC2 0.247 3.788 -1.6923 9.9893
BC-1 GDSC2 0.2538 2.2054 -0.899 4.9952
AMO1 GDSC2 0.2666 1.7401 -0.659 3.4587
Raji GDSC2 0.3443 2.5358 -0.9937 5.3585
JeKo-1 GDSC2 0.3448 2.0392 -0.7484 3.8254
U-698-M GDSC2 0.3616 3.1521 -1.2858 7.1444
Karpas-299 GDSC2 0.4362 2.9724 -1.1402 6.0445
BV-173 GDSC2 0.4396 2.3294 -0.8217 4.0554
WSU-NHL GDSC2 0.4761 8.0215 -3.6212 19.9707
ST486 GDSC2 0.4895 3.3687 -1.2958 6.8823
OCI-AML-3 GDSC2 0.497 2.986 -1.1018 5.6562
LC4-1 GDSC2 0.5075 2.5437 -0.8777 4.2437
L-540 GDSC2 0.5082 5.06 -2.12 11.8839
BALL-1 GDSC2 0.5111 3.9527 -1.5682 8.5194
PF-382 GDSC2 0.5112 2.4071 -0.8088 3.8116
Loucy GDSC2 0.5147 2.5352 -0.8685 4.1709
Mono-Mac-6 GDSC2 0.5326 3.8739 -1.513 8.1231
KE-37 GDSC2 0.5495 3.0994 -1.119 5.6369
Namalwa GDSC2 0.5575 2.3984 -0.7724 3.4877
HL-60 GDSC2 0.567 2.5794 -0.8532 3.9594
HAL-01 GDSC2 0.5751 2.8133 -0.961 4.602
SU-DHL-16 GDSC2 0.5945 2.4974 -0.7947 3.5432
ME1 GDSC2 0.5954 2.6822 -0.8832 4.0794
VAL GDSC2 0.5976 2.8896 -0.9821 4.6806
OCI-M1 GDSC2 0.5977 2.4146 -0.7528 3.2833
697 GDSC2 0.6015 3.2692 -1.1645 5.7954
GR-ST GDSC2 0.6168 3.8903 -1.4581 7.574
Farage GDSC2 0.6228 2.2721 -0.6684 2.7267
SU-DHL-6 GDSC2 0.6254 4.1525 -1.5809 8.3095
P12-Ichikawa GDSC2 0.6257 4.0317 -1.5211 7.9406
BONNA-12 GDSC2 0.6407 4.0621 -1.525 7.9279
DB GDSC2 0.6582 2.4647 -0.7364 3.0604
MOLT-13 GDSC2 0.6589 3.2278 -1.1032 5.2847
RPMI-6666 GDSC2 0.6632 2.7972 -0.8919 3.9849
Reh GDSC2 0.6686 2.2595 -0.6331 2.4302
NALM-6 GDSC2 0.6956 3.3901 -1.1562 5.5264
A3/Kawakami GDSC2 0.7061 2.2663 -0.6127 2.243
NK-92MI GDSC2 0.7112 4.8475 -1.8596 9.7961
YT GDSC2 0.739 3.5962 -1.2256 5.8535
NU-DUL-1 GDSC2 0.7478 2.4724 -0.6824 2.569
MEG-01 GDSC2 0.7589 3.2002 -1.0203 4.5578
BC-3 GDSC2 0.7638 2.7524 -0.8036 3.2487
CTV-1 GDSC2 0.7644 3.5597 -1.1901 5.5789
NKM-1 GDSC2 0.8092 3.2406 -1.0057 4.3628
EB2 GDSC2 0.8118 3.3556 -1.059 4.6786
MHH-CALL-4 GDSC2 0.8118 3.8771 -1.3108 6.209
P31/FUJ GDSC2 0.8146 2.4332 -0.6234 2.1132
NOMO-1 GDSC2 0.8193 3.0274 -0.8974 3.6946
OCI-Ly7 GDSC2 0.8258 2.6121 -0.6988 2.5212
JVM-3 GDSC2 0.8279 2.8811 -0.8229 3.2371
MM1.S GDSC2 0.8343 2.9468 -0.8496 3.3823
L-363 GDSC2 0.8359 2.3508 -0.5735 1.8019
HC-1 GDSC2 0.8402 2.8404 -0.796 3.0564
OPM-2 GDSC2 0.8472 2.9601 -0.8476 3.3454
NB4 GDSC2 0.8582 2.0214 -0.4169 0.9584
RPMI-8226 GDSC2 0.8664 2.8133 -0.7668 2.8387
PL-21 GDSC2 0.8836 3.348 -1.0072 4.2186
KMS-12-BM GDSC2 0.8876 5.235 -1.9196 9.7218
MOLP-8 GDSC2 0.8905 3.0748 -0.8737 3.4152
BE-13 GDSC2 0.8977 3.5847 -1.1107 4.8092
ML-2 GDSC2 0.8984 3.0412 -0.853 3.279
IM-9 GDSC2 0.9007 2.6099 -0.6526 2.1323
JVM-2 GDSC2 0.91 3.989 -1.2965 5.9039
ALL-SIL GDSC2 0.9175 3.4122 -1.0154 4.1988
SIG-M5 GDSC2 0.9306 2.4745 -0.5748 1.6631
Ku812 GDSC2 0.931 3.1036 -0.8616 3.2677
TALL-1 [Human adult T-ALL] GDSC2 0.9382 3.5392 -1.0621 4.435
RS4;11 GDSC2 0.9428 4.1346 -1.3441 6.1204
RC-K8 GDSC2 0.9778 3.1787 -0.8672 3.2135
SU-DHL-4 GDSC2 1.0045 2.3612 -0.4858 1.1117
HEL GDSC2 1.0047 2.8599 -0.7048 2.2507
Karpas-422 GDSC2 1.0176 5.2934 -1.854 9.021
Jiyoye GDSC2 1.0383 3.537 -0.9962 3.8494
GA-10 GDSC2 1.0427 3.5261 -0.9883 3.7955
P32/ISH GDSC2 1.1003 2.641 -0.5555 1.3311
CA46 GDSC2 1.1104 4.0405 -1.1867 4.8287
EM-2 GDSC2 1.1473 4.0313 -1.1585 4.5904
MOLM-16 GDSC2 1.1702 2.9129 -0.6356 1.639
MHH-CALL-2 GDSC2 1.1704 3.2918 -0.8031 2.5233
A4/Fukuda GDSC2 1.1719 3.5997 -0.9423 3.2964
K-562 GDSC2 1.1819 2.9021 -0.6247 1.5687
Hs 445 GDSC2 1.1823 2.9088 -0.6274 1.5814
OCI-AML-2 GDSC2 1.2113 2.4307 -0.4151 0.595
MOLT-4 GDSC2 1.2274 4.1838 -1.1789 4.5558
P30/OHK GDSC2 1.2296 2.9438 -0.6175 1.4716
ALL-PO GDSC2 1.2748 3.5608 -0.8637 2.6881
LAMA-84 GDSC2 1.283 3.0811 -0.6484 1.5553
SUP-HD1 GDSC2 1.3257 4.3423 -1.1909 4.4412
NCI-H929 GDSC2 1.326 3.2437 -0.6956 1.7334
KMS-11 GDSC2 1.3346 6.9766 -2.4483 11.7106
L-1236 GDSC2 1.3506 5.1961 -1.577 6.646
SUP-M2 GDSC2 1.3672 2.6035 -0.4143 0.4764
SK-MM-2 GDSC2 1.3691 3.4739 -0.7723 2.0638
SUP-T1 GDSC2 1.3705 3.5516 -0.8056 2.2338
RCH-ACV GDSC2 1.377 3.3431 -0.7115 1.7459
Karpas-620 GDSC2 1.383 5.2628 -1.5873 6.6401
U266B1 GDSC2 1.3835 3.6531 -0.8431 2.4117
Ramos.2G6.4C10 GDSC2 1.3861 2.6763 -0.4341 0.5314
MN-60 GDSC2 1.4031 3.6181 -0.8169 2.246
HH [Human lymphoma] GDSC2 1.4061 3.8369 -0.9121 2.7451
SU-DHL-10 GDSC2 1.4089 2.6024 -0.3964 0.3929
Jurkat GDSC2 1.4215 5.5575 -1.702 7.2323
CESS GDSC2 1.4298 4.0634 -1.0001 3.1857
Karpas-1106P GDSC2 1.468 3.3224 -0.656 1.3704
CCRF-CEM GDSC2 1.4736 3.1245 -0.5719 0.9925
SCC-3 GDSC2 1.4763 2.5968 -0.3674 0.2754
H9 GDSC2 1.4795 5.0615 -1.4296 5.5308
JSC-1 GDSC2 1.482 3.8624 -0.8808 2.466
KMOE-2 GDSC2 1.502 3.5444 -0.7324 1.691
Daudi GDSC2 1.5241 4.3813 -1.0886 3.5192
MY-M12 GDSC2 1.5269 3.6132 -0.7488 1.7393
SU-DHL-8 GDSC2 1.5712 3.1992 -0.5568 0.8425
RL GDSC2 1.5835 47.3002 -22.3438 42.2117
SUP-B15 GDSC2 1.5888 3.7462 -0.7734 1.7824
EJM GDSC2 1.5897 3.8956 -0.8369 2.0929
DoHH2 GDSC2 1.6014 3.0257 -0.4762 0.528
KY821 GDSC2 1.6166 3.2303 -0.5487 0.7737
ATN-1 GDSC2 1.646 3.3447 -0.5806 0.872
JJN-3 GDSC2 1.6509 3.223 -0.5307 0.6812
L-428 GDSC2 1.701 3.3456 -0.5564 0.7368
Karpas-231 GDSC2 1.7011 3.3933 -0.575 0.8054
KM-H2 GDSC2 1.7259 5.7121 -1.5779 5.917
VL51 GDSC2 1.7391 3.5551 -0.6218 0.9543
CML-T1 GDSC2 1.7648 3.5008 -0.5889 0.807
MHH-PREB-1 GDSC2 1.7723 3.3718 -0.5358 0.6137
LP-1 GDSC2 1.7727 3.3967 -0.5452 0.645
DG-75 GDSC2 1.7833 3.8856 -0.7347 1.3844
KCL-22 GDSC2 1.8396 3.7637 -0.659 1.0144
KOPN-8 GDSC2 1.8538 3.5137 -0.5554 0.6252
ARH-77 GDSC2 1.8909 3.6732 -0.6007 0.7549
WIL2 NS GDSC2 1.9784 3.6474 -0.5541 0.5438
BL-41 GDSC2 1.9868 3.4435 -0.4759 0.3242
MOLT-16 GDSC2 2.0325 3.3545 -0.4272 0.2025
ROS-50 GDSC2 2.0719 6.1638 -1.5743 5.2826
Granta-519 GDSC2 2.0807 3.602 -0.4969 0.3359
OCI-Ly19 GDSC2 2.1051 4.0808 -0.6656 0.8291
KG-1 GDSC2 2.118 3.9566 -0.6127 0.6429
TK [Human B-cell lymphoma] GDSC2 2.1952 3.8701 -0.5495 0.4179
HDLM-2 GDSC2 2.3521 4.2977 -0.6443 0.6029
DND-41 GDSC2 2.5427 4.3812 -0.5998 0.3928
QIMR-WIL GDSC2 2.5908 5.0545 -0.8315 1.0641
CRO-AP2 GDSC2 2.7638 4.7256 -0.6389 0.3966
Karpas-45 GDSC2 2.8969 4.9181 -0.6571 0.3876
⏷ Show the Full List of 162 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYAE-1 GDSC2 -2.2705 1.3205 -2.9316 26.2878
TE-12 GDSC2 0.4631 7.6285 -3.4355 19.1319
ESO-26 GDSC2 0.6181 3.005 -1.0237 4.8892
OACP4 C GDSC2 0.8097 3.4534 -1.1074 4.976
KYSE-50 GDSC2 0.8614 4.7604 -1.7061 8.5006
KYSE-220 GDSC2 1.0332 5.1091 -1.7531 8.382
FLO-1 GDSC2 1.0837 6.4887 -2.3915 11.9924
HCE-4 GDSC2 1.6654 5.7557 -1.6365 6.366
SK-GT-4 GDSC2 2.1474 10.2451 -3.462 15.0509
ESO-51 GDSC2 2.1747 4.3856 -0.7538 1.1008
OACM5.1 C GDSC2 2.4326 4.8324 -0.8144 1.1223
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 2.3864 4.872 -0.8507 1.2993
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB69 GDSC2 -0.8924 2.8809 -2.2381 16.9104
NB(TU)1 GDSC2 0.2729 3.991 -1.7729 10.4164
CHP-126 GDSC2 0.4231 2.7897 -1.0599 5.5755
KP-N-YS GDSC2 0.4641 3.0893 -1.177 6.205
CHP-134 GDSC2 0.4842 4.0274 -1.6258 8.9442
SJNB-17 GDSC2 0.4872 10.7759 -4.9875 25.4006
SJNB-13 GDSC2 0.5671 2.9125 -1.015 4.9529
SK-N-FI GDSC2 0.6254 8.4545 -3.718 19.9991
SJNB-14 GDSC2 0.6601 2.7553 -0.8739 3.8827
KP-N-YN GDSC2 0.6921 3.081 -1.0088 4.6331
Kelly GDSC2 0.7042 3.9077 -1.4026 7.021
LA-N-6 GDSC2 0.7157 5.256 -2.058 10.9738
IMR-5 GDSC2 0.7237 2.9003 -0.9004 3.9079
MHH-NB-11 GDSC2 0.8822 7.3314 -2.9589 15.5987
SK-N-MC-IXC GDSC2 0.8969 10.0878 -4.3174 21.8197
SK-N-BE(2)-M17 GDSC2 0.9117 3.5306 -1.0755 4.569
SiMa GDSC2 0.9297 5.0634 -1.8049 8.9343
NH-12 GDSC2 0.953 5.0754 -1.794 8.8135
GOTO GDSC2 0.9706 9.3018 -3.8688 19.7452
SJNB-10 GDSC2 0.978 3.2498 -0.9002 3.4042
CHP-212 GDSC2 1.0382 3.573 -1.0131 3.9489
SK-N-DZ GDSC2 1.0727 5.8858 -2.1039 10.3653
KP-N-RT-BM-1 GDSC2 1.17 4.0438 -1.1498 4.4959
NB1 GDSC2 1.3087 4.8087 -1.4207 5.8125
SK-N-SH GDSC2 1.3173 4.2926 -1.173 4.3541
SJNB-7 GDSC2 1.3757 4.0111 -1.0082 3.3188
TGW GDSC2 1.4045 4.1291 -1.0447 3.4739
SK-N-AS GDSC2 2.0879 4.8358 -0.9794 2.1647
GI-ME-N GDSC2 2.1329 8.3927 -2.5795 10.6664
SJNB-5 GDSC2 2.2026 9.6796 -3.1499 13.4336
SJNB-6 GDSC2 2.2035 3.8588 -0.5422 0.3953
SJNB-12 GDSC2 2.4977 10.5659 -3.3742 13.8839
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 0.3578 4.8847 -2.151 12.4764
Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC2218 GDSC2 -3.3639 -1.2027 -3.4262 34.0625
MDA-MB-175-VII GDSC2 -3.1696 -0.7199 -3.2925 32.4158
UACC-893 GDSC2 -2.328 3.7387 -4.0424 31.5879
MDA-MB-330 GDSC2 -2.1024 3.6702 -3.7866 29.59
AU565 GDSC2 -1.8202 3.456 -3.408 26.7292
HDQ-P1 GDSC2 -1.5657 6.0465 -4.41 29.8848
ZR-75-30 GDSC2 -0.6076 6.1113 -3.5757 23.0642
OCUB-M GDSC2 -0.5422 3.3571 -2.1494 15.1839
HCC1806 GDSC2 -0.0267 5.1695 -2.6071 16.2321
UACC-812 GDSC2 0.0102 4.4176 -2.2003 13.7625
HCC1419 GDSC2 0.0262 4.5113 -2.2338 13.9147
BT-474 GDSC2 0.0575 6.2716 -3.088 18.576
HCC1569 GDSC2 0.0891 7.7781 -3.8151 21.9662
DU4475 GDSC2 0.1984 2.4202 -1.049 6.0868
EFM-192A GDSC2 0.3859 7.1227 -3.2451 18.4171
MDA-MB-453 GDSC2 0.3878 2.5352 -0.9608 5.0441
HCC2157 GDSC2 0.426 3.8109 -1.5631 8.7073
CAL-148 GDSC2 0.483 5.5422 -2.3796 13.4735
HCC1599 GDSC2 0.5106 2.9288 -1.0637 5.3869
COLO 824 GDSC2 0.5317 3.8037 -1.479 7.9145
YMB-1-E GDSC2 0.9083 3.7144 -1.1656 5.117
MDA-MB-361 GDSC2 0.919 4.1543 -1.37 6.3295
MDA-MB-415 GDSC2 0.9755 2.8777 -0.73 2.4384
BT-549 GDSC2 0.9938 4.5139 -1.492 6.9011
MFM-223 GDSC2 1.0259 3.4167 -0.9478 3.5916
CAMA-1 GDSC2 1.086 5.2275 -1.7733 8.3824
HCC1954 GDSC2 1.1295 4.6012 -1.441 6.301
MDA-MB-436 GDSC2 1.2797 3.4944 -0.8311 2.504
BT-483 GDSC2 1.2964 3.8498 -0.9818 3.305
HCC38 GDSC2 1.343 3.8752 -0.9658 3.138
MDA-MB-468 GDSC2 1.4286 7.9784 -2.8703 13.7701
HCC1937 GDSC2 1.4675 7.7436 -2.7274 12.9216
HCC1143 GDSC2 1.5144 6.4972 -2.0896 9.2778
HCC1187 GDSC2 1.5301 5.5955 -1.6484 6.6993
HCC1395 GDSC2 1.5657 3.6971 -0.7645 1.7675
HCC70 GDSC2 1.5847 4.8159 -1.2505 4.3179
T-47D GDSC2 1.6169 6.9917 -2.2573 10.0043
CAL-120 GDSC2 1.6212 3.8078 -0.7829 1.7884
HCC1428 GDSC2 1.7117 3.8946 -0.7736 1.6378
BT-20 GDSC2 1.7532 3.5652 -0.6194 0.933
MRK-nu-1 GDSC2 1.7636 3.3493 -0.5309 0.6031
JIMT-1 GDSC2 1.8002 3.1847 -0.4546 0.3531
CAL-51 GDSC2 1.8062 8.606 -2.9065 13.0828
Hs 578T GDSC2 1.8068 6.1145 -1.7147 6.5416
EFM-19 GDSC2 1.8481 10.62 -3.8596 17.5341
HCC1500 GDSC2 1.9249 3.9749 -0.7042 1.1199
MCF-7 GDSC2 2.126 4.6868 -0.8983 1.7492
MDA-MB-157 GDSC2 2.2263 4.4386 -0.7516 1.0507
MDA-MB-231 GDSC2 2.254 4.1051 -0.6125 0.5632
Evsa-T GDSC2 2.2768 3.9383 -0.5425 0.3647
CAL-85-1 GDSC2 2.8873 4.9835 -0.6842 0.4534
⏷ Show the Full List of 51 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC2 0.0969 4.186 -2.0128 12.3812
D-247MG GDSC2 0.6537 3.0129 -1.0026 4.6797
SNB-75 GDSC2 0.7569 4.1107 -1.4638 7.2719
SF126 GDSC2 0.7945 4.6267 -1.6893 8.559
U-118MG GDSC2 0.8154 3.7768 -1.2596 5.8885
42-MG-BA GDSC2 0.8518 3.3152 -1.0128 4.317
D-336MG GDSC2 0.8839 9.0997 -3.8359 19.8287
U-87MG ATCC GDSC2 0.9487 3.5036 -1.0382 4.2719
Hs 683 GDSC2 0.9819 2.5965 -0.6001 1.7207
D-502MG GDSC2 1.0267 7.4219 -2.8939 14.8844
NMC-G1 GDSC2 1.0566 6.4398 -2.3874 12.0356
SF539 GDSC2 1.0834 4.7453 -1.5417 7.0025
PFSK-1 GDSC2 1.1092 6.4036 -2.331 11.5873
AM-38 GDSC2 1.1582 4.3465 -1.3004 5.4053
D-542MG GDSC2 1.1684 5.7092 -1.9492 9.2353
DBTRG-05MG GDSC2 1.1725 4.9846 -1.5957 7.1319
KNS-81-FD GDSC2 1.1787 3.6822 -0.9761 3.4763
SF295 GDSC2 1.1839 5.171 -1.6777 7.5946
D-245MG GDSC2 1.2451 4.2547 -1.2008 4.6498
GaMG GDSC2 1.3001 3.5407 -0.8402 2.5218
SK-MG-1 GDSC2 1.3081 4.0554 -1.069 3.776
A-172 GDSC2 1.3191 7.6541 -2.7911 13.615
KALS-1 GDSC2 1.3282 4.0979 -1.0763 3.7823
SW1783 GDSC2 1.4527 5.0984 -1.464 5.7819
U-251MG GDSC2 1.4662 5.8314 -1.8029 7.7267
ONS-76 GDSC2 1.4883 4.2309 -1.0415 3.3187
D-392MG GDSC2 1.5046 4.3543 -1.0878 3.5468
D-566MG GDSC2 1.5117 3.2719 -0.6138 1.1343
GI-1 GDSC2 1.5459 3.7081 -0.7794 1.8647
KNS-42 GDSC2 1.576 3.8647 -0.8308 2.0805
CAS-1 GDSC2 1.578 3.5139 -0.6813 1.3639
LN-18 GDSC2 1.6059 2.6977 -0.3541 0.1931
T98G GDSC2 1.6121 3.5066 -0.6617 1.2408
GB-1 GDSC2 1.6437 3.3293 -0.5755 0.8542
Onda 11 GDSC2 1.6459 4.7336 -1.1766 3.8043
SF268 GDSC2 1.7021 4.1309 -0.8788 2.1546
YKG-1 GDSC2 1.7076 8.1671 -2.7628 12.5565
MOG-G-UVW GDSC2 1.7196 3.9134 -0.7775 1.6469
D-263MG GDSC2 1.7912 3.5738 -0.6057 0.8491
H4 GDSC2 1.8 4.4344 -0.9577 2.4199
M059J GDSC2 1.8064 3.9205 -0.7378 1.3744
Becker GDSC2 1.8198 5.2936 -1.328 4.3513
Onda 10 GDSC2 1.8404 3.9339 -0.7271 1.2941
MOG-G-CCM GDSC2 1.8681 4.8828 -1.1164 3.1387
DK-MG GDSC2 1.9049 11.6282 -4.313 19.3056
KS-1 [Human Krukenberg tumour] GDSC2 1.9268 5.2253 -1.2353 3.6788
KINGS-1 GDSC2 2.0106 4.424 -0.8461 1.6391
SW1088 GDSC2 2.0145 7.653 -2.3059 9.4361
LN-405 GDSC2 2.0746 3.9426 -0.6256 0.7129
YH-13 GDSC2 2.1095 10.9976 -3.8553 16.9158
Daoy GDSC2 2.2169 4.8126 -0.906 1.6885
LN-229 GDSC2 2.2841 9.3295 -2.9259 12.1444
8-MG-BA GDSC2 2.303 4.3619 -0.6888 0.7726
D-423MG GDSC2 2.4108 15.9063 -6.0444 24.0919
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 -0.0261 5.837 -2.9403 18.0539
ETK-1 GDSC2 1.0299 9.6199 -3.9809 20.077
TGBC1TKB GDSC2 1.1155 10.7169 -4.4596 21.8121
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KLE GDSC2 0.8076 8.0212 -3.3591 17.8174
RL95-2 GDSC2 0.872 3.8201 -1.2412 5.6518
MFE-319 GDSC2 1.1557 4.5213 -1.3852 5.9138
MFE-280 GDSC2 1.4994 5.9482 -1.8364 7.8518
MFE-296 GDSC2 1.5232 4.2116 -1.0127 3.1064
EN GDSC2 1.6044 5.4409 -1.5279 5.8598
AN3-CA GDSC2 1.6617 6.8125 -2.1407 9.2515
ESS-1 GDSC2 2.0725 3.8358 -0.5861 0.5869
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW13 GDSC2 -1.9851 1.1333 -2.5547 23.0119
CAL-54 GDSC2 -1.2796 6.1904 -4.2171 28.116
Caki-1 GDSC2 -0.2068 4.9985 -2.6736 17.1557
LB1047-RCC GDSC2 -0.1593 3.3931 -1.831 12.0271
A-498 GDSC2 0.3093 3.9898 -1.7434 10.1348
LB996-RCC GDSC2 0.4661 7.1867 -3.2127 18.0286
BFTC-909 GDSC2 0.4993 2.4718 -0.8485 4.0829
RCC10RGB GDSC2 0.5457 10.5266 -4.8157 24.6424
KTCTL-26A GDSC2 0.564 3.9431 -1.5235 8.1088
769-P GDSC2 0.5645 3.8195 -1.4621 7.7276
TK-10 GDSC2 0.5792 5.0075 -2.0389 11.2128
ACHN GDSC2 0.7188 7.6919 -3.2645 17.5913
NCC010 GDSC2 0.7896 7.1672 -2.9487 15.7886
UO-31 GDSC2 0.827 6.4483 -2.5635 13.6046
BB65-RCC GDSC2 0.8438 3.3462 -1.0329 4.4542
KTCTL-21 GDSC2 0.8661 10.2239 -4.4093 22.2644
KTCTL-13 GDSC2 0.8849 4.6971 -1.6582 8.1552
A-704 GDSC2 0.9018 4.6651 -1.6304 7.9473
HA7-RCC GDSC2 0.9172 4.8261 -1.6979 8.3197
SN12C GDSC2 1.0872 4.8707 -1.5996 7.3416
VMRC-RCZ GDSC2 1.2572 6.7761 -2.406 11.6571
SW156 GDSC2 1.2967 4.3821 -1.2277 4.708
KTCTL-140 GDSC2 1.368 4.4337 -1.207 4.4563
LB2241-RCC GDSC2 1.4442 6.0244 -1.9102 8.3962
VMRC-RCW GDSC2 1.4747 7.0007 -2.3605 10.8983
OS-RC-2 GDSC2 1.4761 5.8839 -1.8213 7.8134
KTCTL-195 GDSC2 1.5204 4.8089 -1.2865 4.6343
786-O GDSC2 1.6116 6.6842 -2.1132 9.2025
KTCTL-1M GDSC2 1.8001 4.4584 -0.9681 2.4716
NCC021 GDSC2 1.8623 8.1459 -2.6448 11.588
KMRC-20 GDSC2 1.8967 3.4222 -0.5035 0.4394
RXF 393L GDSC2 2.8118 7.6917 -1.8323 5.465
KMRC-1 GDSC2 4.4561 17.2592 -5.2581 17.621
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DiFi GDSC2 -3.2033 0.4107 -3.6161 34.0777
CCK-81 GDSC2 -1.7409 1.7375 -2.5489 21.9485
SW48 GDSC2 -1.5464 9.2869 -5.9877 34.4154
NCI-H508 GDSC2 -1.5336 3.8045 -3.2939 25.0417
COLO 320HSR GDSC2 -0.7621 1.1941 -1.3097 10.8109
CW-2 GDSC2 -0.5714 3.4232 -2.2083 15.6332
LoVo GDSC2 -0.4219 4.5592 -2.6401 17.6484
SNU-175 GDSC2 0.0567 4.2346 -2.0703 12.8462
SK-CO-1 GDSC2 0.2742 5.0342 -2.2924 13.5451
GP5d GDSC2 0.3189 2.2318 -0.8626 4.6013
NCI-H747 GDSC2 0.3506 4.1977 -1.8143 10.4592
HT115 GDSC2 0.4976 2.2403 -0.7374 3.4053
HT-55 GDSC2 0.5338 4.0082 -1.5785 8.5249
LS123 GDSC2 0.5484 4.5256 -1.8236 9.9924
SW1463 GDSC2 0.5882 6.4572 -2.7525 15.28
LS1034 GDSC2 0.6759 4.4227 -1.6764 8.7704
LS411N GDSC2 0.714 3.7632 -1.3248 6.52
COLO205 GDSC2 0.7714 7.6008 -3.1782 17.0181
LS180 GDSC2 0.7716 3.2793 -1.0497 4.7087
SW1116 GDSC2 0.8504 6.1252 -2.386 12.5428
SW948 GDSC2 0.858 3.9493 -1.3134 6.1214
SNU-C5 GDSC2 0.8667 3.3903 -1.0386 4.4409
CaR-1 GDSC2 0.8803 5.0615 -1.8399 9.2621
HT-29 GDSC2 0.9057 3.8236 -1.2198 5.4497
SNU-283 GDSC2 0.9143 6.5979 -2.5714 13.4242
SNU-61 GDSC2 0.9979 3.2215 -0.8745 3.2194
T84 GDSC2 1.0048 3.9529 -1.2148 5.2104
HCT 116 GDSC2 1.1636 5.0972 -1.6561 7.5107
C2BBe1 GDSC2 1.2146 5.3278 -1.7322 7.8511
SNU-407 GDSC2 1.2844 5.1195 -1.5846 6.8281
SW837 GDSC2 1.3237 8.12 -3.0166 14.7819
SNU-81 GDSC2 1.3536 4.4031 -1.2017 4.4524
COLO 678 GDSC2 1.4703 7.1306 -2.4267 11.2768
SNU-C1 GDSC2 1.5688 3.6324 -0.7354 1.6248
KM12 GDSC2 1.5879 3.3952 -0.6278 1.1183
HCC2998 GDSC2 1.6047 4.4158 -1.0574 3.2209
RCM-1 [Human ESC] GDSC2 1.614 8.1893 -2.84 13.1761
SW1417 GDSC2 1.6149 4.917 -1.2786 4.4234
MDST8 GDSC2 1.6823 3.8819 -0.7831 1.7161
SNU-C2B GDSC2 1.7271 7.2222 -2.2929 9.9645
CL-11 GDSC2 1.8326 5.7127 -1.512 5.3516
SW626 GDSC2 1.8641 4.6567 -1.0197 2.6462
HCT 15 GDSC2 1.9766 9.543 -3.2415 14.3785
RKO GDSC2 1.9828 3.6876 -0.5674 0.5822
SW620 GDSC2 2.0272 4.8992 -1.0377 2.5213
NCI-H716 GDSC2 2.0922 3.9074 -0.6048 0.6338
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 1.798 3.5584 -0.5967 0.8103
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-6 GDSC2 0.8497 2.7027 -0.7259 2.6338
JHH-4 GDSC2 0.8942 11.8615 -5.203 25.0466
SNU-387 GDSC2 1.0002 7.9543 -3.1774 16.4125
JHH-1 GDSC2 1.0629 6.3257 -2.3267 11.6748
Hep-G2/C3A GDSC2 1.265 4.9645 -1.5236 6.5081
Huh-7 GDSC2 1.337 7.5434 -2.7238 13.2117
HLE GDSC2 1.3753 5.8895 -1.8924 8.4415
JHH-7 GDSC2 1.4409 5.3297 -1.5809 6.4855
SNU-398 GDSC2 1.5255 6.1839 -1.9316 8.3471
SNU-423 GDSC2 1.6377 4.2199 -0.952 2.6137
HuH-1 GDSC2 1.6509 3.2028 -0.5229 0.6534
Hep 3B2.1-7 GDSC2 1.7186 16.1787 -6.7055 27.3785
JHH-2 GDSC2 1.7953 6.392 -1.8523 7.3442
SK-HEP-1 GDSC2 2.2717 3.5969 -0.425 0.1384
SNU-449 GDSC2 2.8447 11.4111 -3.5443 13.9561
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 182 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PC-14 GDSC2 -4.5948 4.5227 -6.7001 47.9106
HCC827 GDSC2 -4.4969 3.3485 -6.1021 47.0648
NCI-H1975 GDSC2 -4.4796 6.5657 -7.491 47.6868
NCI-H3255 GDSC2 -3.6892 3.9988 -5.5393 42.1143
PaCa-3 GDSC2 -3.5643 5.553 -6.1106 42.4052
NCI-H2170 GDSC2 -3.4859 1.111 -4.1566 37.6874
COR-L105 GDSC2 -2.5344 1.7176 -3.3698 29.6604
NCI-H322M GDSC2 -2.0321 3.0015 -3.4087 27.6127
NCI-H1648 GDSC2 -1.4108 1.3132 -2.0248 17.603
NCI-H292 GDSC2 -1.3974 5.9771 -4.2204 28.5563
RERF-LC-Sq1 GDSC2 -0.8464 3.8247 -2.6566 19.1635
Calu-3 GDSC2 -0.7107 1.9534 -1.6177 12.5087
NCI-H1781 GDSC2 -0.6141 3.7556 -2.4113 16.9709
EMC-BAC-1 GDSC2 -0.3107 4.3225 -2.4253 16.0672
NCI-H1666 GDSC2 -0.1952 6.3762 -3.3522 20.6755
NCI-H1869 GDSC2 0.0564 5.1031 -2.5047 15.4036
NCI-H2110 GDSC2 0.0643 3.7416 -1.8175 11.2801
LB647-SCLC GDSC2 0.2762 2.3391 -0.9481 5.2459
CAL-12T GDSC2 0.2774 8.7424 -4.1422 22.8137
NCI-H1623 GDSC2 0.2921 4.625 -2.0738 12.1965
NCI-H358 GDSC2 0.3447 7.1511 -3.2925 18.7703
NCI-H748 GDSC2 0.3584 2.7095 -1.0689 5.7938
HCC33 GDSC2 0.3824 2.8991 -1.1445 6.2067
NCI-H2141 GDSC2 0.3998 5.3541 -2.3516 13.5399
COR-L279 GDSC2 0.4182 2.6316 -0.9856 5.1243
NCI-H211 GDSC2 0.4306 4.8274 -2.0649 11.7634
NCI-H2795 GDSC2 0.4965 4.9507 -2.0747 11.6452
EKVX GDSC2 0.524 6.4287 -2.7888 15.6527
NCI-H146 GDSC2 0.5325 2.953 -1.0596 5.3096
NCI-H647 GDSC2 0.5459 3.0056 -1.0757 5.3773
NCI-H1755 GDSC2 0.5526 4.1218 -1.6204 8.7359
HCC78 GDSC2 0.5728 5.0173 -2.0487 11.2881
LCLC-103H GDSC2 0.5889 2.0803 -0.5999 2.3883
NCI-H838 GDSC2 0.5933 6.0776 -2.5596 14.1992
NCI-H847 GDSC2 0.6447 2.3738 -0.7022 2.8836
LC-1/sq GDSC2 0.6504 5.3266 -2.1426 11.6432
COR-L88 GDSC2 0.6628 3.5772 -1.2708 6.3072
NCI-H2085 GDSC2 0.6789 3.9223 -1.4281 7.2386
RERF-LC-KJ GDSC2 0.6967 3.2876 -1.1056 5.214
COR-L303 GDSC2 0.702 2.1216 -0.5485 1.8848
BEN GDSC2 0.7124 7.9157 -3.381 18.1802
NCI-H2122 GDSC2 0.7167 3.5351 -1.2117 5.8186
NCI-H64 GDSC2 0.751 4.4058 -1.6126 8.1967
NCI-H2196 GDSC2 0.7564 3.1907 -1.0175 4.5461
SBC-5 GDSC2 0.7607 5.2473 -2.0199 10.6333
NCI-H1693 GDSC2 0.7616 5.544 -2.1657 11.4931
SHP-77 GDSC2 0.7676 3.1745 -1.0021 4.4287
NCI-H513 GDSC2 0.7763 5.9816 -2.371 12.6471
COR-L32 GDSC2 0.8047 3.3065 -1.0402 4.5806
NCI-H1876 GDSC2 0.8085 2.9198 -0.8536 3.4564
NCI-H2023 GDSC2 0.815 2.6157 -0.7071 2.5887
NCI-H2291 GDSC2 0.824 3.4069 -1.0753 4.7514
NCI-H250 GDSC2 0.8241 3.2154 -0.9836 4.199
NCI-H2030 GDSC2 0.8636 5.0307 -1.837 9.285
NCI-H1568 GDSC2 0.873 8.527 -3.5596 18.6004
CPC-N GDSC2 0.8737 3.3691 -1.0238 4.338
NCI-H2818 GDSC2 0.8822 3.5468 -1.103 4.7952
COR-L23 GDSC2 0.91 3.4038 -1.0164 4.2196
Lu-165 GDSC2 0.9212 2.544 -0.6111 1.8716
NCI-H82 GDSC2 0.9333 2.5461 -0.6051 1.821
NCI-H460 GDSC2 0.9476 4.0321 -1.2914 5.7919
IST-SL1 GDSC2 0.9487 3.1123 -0.8545 3.1938
Ms-1 GDSC2 0.9509 2.6255 -0.6306 1.931
NCI-H510A GDSC2 0.9517 3.9705 -1.259 5.5871
NCI-H1963 GDSC2 0.9665 5.6702 -2.0755 10.4538
SK-MES-1 GDSC2 0.9818 6.271 -2.3596 12.0623
LC-2/ad GDSC2 0.9846 3.7198 -1.1172 4.669
NCI-H2444 GDSC2 0.9879 2.4549 -0.5348 1.3747
NCI-H3122 GDSC2 0.988 4.0354 -1.2655 5.5492
NCI-H2461 GDSC2 1.046 3.9873 -1.2038 5.0596
NCI-H841 GDSC2 1.0625 4.6442 -1.5073 6.8422
HARA [Human squamous cell lung carcinoma] GDSC2 1.0648 8.2776 -3.2884 16.7976
NCI-H526 GDSC2 1.0699 2.7192 -0.6055 1.6231
EPLC-272H GDSC2 1.0845 13.6947 -5.9659 26.8951
NCI-H810 GDSC2 1.0853 7.322 -2.8006 14.2409
NCI-H446 GDSC2 1.0867 4.9393 -1.6331 7.543
Lu-134-A GDSC2 1.0977 4.627 -1.475 6.5719
NCI-H69 GDSC2 1.101 3.6894 -1.0278 3.9154
NCI-H2009 GDSC2 1.1073 4.5259 -1.4199 6.2223
LK-2 GDSC2 1.1389 7.4014 -2.7998 14.1026
NCI-H720 GDSC2 1.1431 3.0851 -0.7262 2.1501
UMC-11 GDSC2 1.1446 5.0008 -1.6227 7.3534
IST-SL2 GDSC2 1.1487 3.7555 -1.0286 3.8313
NCI-H2172 GDSC2 1.1625 4.855 -1.5403 6.8235
NCI-H345 GDSC2 1.1751 2.6488 -0.5207 1.0764
COR-L311 GDSC2 1.2096 3.2648 -0.7686 2.2758
NCI-H1792 GDSC2 1.2147 3.2792 -0.7721 2.287
NCI-H1793 GDSC2 1.2282 5.9028 -2.001 9.4028
Calu-6 GDSC2 1.2488 3.3669 -0.7919 2.3409
COR-L321 GDSC2 1.2556 3.4612 -0.83 2.5356
NCI-H1915 GDSC2 1.2808 4.7563 -1.4142 5.83
NCI-H1651 GDSC2 1.2841 3.6701 -0.9076 2.9133
HOP-62 GDSC2 1.2851 4.241 -1.1692 4.3912
NCI-H661 GDSC2 1.2874 4.8154 -1.4379 5.9562
NCI-H740 GDSC2 1.2969 3.8235 -0.9696 3.2359
NCI-H2029 GDSC2 1.301 5.6289 -1.8178 8.1671
NCI-H2227 GDSC2 1.3068 14.533 -6.2082 27.0305
HCC366 GDSC2 1.309 19.8023 -8.8325 32.5791
NCI-H1155 GDSC2 1.32 3.5111 -0.8158 2.3615
NCI-H522 GDSC2 1.3242 7.6318 -2.7764 13.5243
NCI-H2081 GDSC2 1.3365 3.8297 -0.949 3.056
NCI-H1993 GDSC2 1.3453 3.3232 -0.7197 1.8287
NCI-H1563 GDSC2 1.3577 6.7126 -2.3031 10.8428
NCI-H196 GDSC2 1.3586 4.0158 -1.0204 3.4156
NCI-H2228 GDSC2 1.3594 7.7348 -2.8013 13.5719
NCI-H1581 GDSC2 1.3626 4.284 -1.141 4.0887
NCI-H1436 GDSC2 1.3647 3.148 -0.6348 1.39
NCI-H2369 GDSC2 1.3766 2.6993 -0.4471 0.5847
NCI-H2066 GDSC2 1.3873 3.5135 -0.7797 2.0766
NCI-H1435 GDSC2 1.39 7.2892 -2.5612 12.2045
HCC44 GDSC2 1.4194 5.5712 -1.7099 7.2827
LOU-NH91 GDSC2 1.422 12.7484 -5.2314 23.8222
NCI-H226 GDSC2 1.449 4.0986 -1.0048 3.1808
DMS 53 GDSC2 1.4756 5.0468 -1.4252 5.5126
NCI-H2373 GDSC2 1.4939 4.3158 -1.0767 3.5027
SW1271 GDSC2 1.4988 4.3659 -1.0965 3.6041
NCI-H2722 GDSC2 1.5094 6.7694 -2.2243 10.0545
NCI-H1299 GDSC2 1.5152 3.6897 -0.7876 1.9445
NCI-H1944 GDSC2 1.5247 9.1675 -3.3835 16.116
Lu-99A GDSC2 1.5296 5.2572 -1.4894 5.7805
IA-LM GDSC2 1.5573 3.8082 -0.8163 2.0327
Lu-65 GDSC2 1.5586 4.2172 -0.995 2.9565
NCI-H2171 GDSC2 1.5656 2.8686 -0.4318 0.4101
NCI-H2087 GDSC2 1.567 3.7867 -0.802 1.9491
NCI-H2810 GDSC2 1.5712 4.2509 -1.0029 2.9795
SK-LU-1 GDSC2 1.5718 3.519 -0.6865 1.3943
NCI-H1573 GDSC2 1.5841 3.1896 -0.5472 0.7945
NCI-H1836 GDSC2 1.5915 3.2693 -0.5754 0.8986
NCI-H727 GDSC2 1.5971 4.7389 -1.2078 4.0583
NCI-H1092 GDSC2 1.6134 4.6979 -1.1795 3.8736
NCI-H1838 GDSC2 1.6198 4.4333 -1.0566 3.1932
NCI-H2135 GDSC2 1.6262 3.0818 -0.4871 0.5479
HCC15 GDSC2 1.6317 5.6205 -1.5946 6.1906
NCI-H441 GDSC2 1.6334 3.7279 -0.743 1.5852
NCI-H2804 GDSC2 1.6393 5.1663 -1.3784 4.9431
NCI-H2595 GDSC2 1.6509 4.2682 -0.966 2.6678
NCI-H2347 GDSC2 1.6515 5.2548 -1.4118 5.1104
NCI-H2405 GDSC2 1.653 3.7757 -0.7532 1.6102
NCI-H2869 GDSC2 1.6585 5.078 -1.326 4.6138
LXF 289 GDSC2 1.6702 7.835 -2.628 11.9232
A-427 GDSC2 1.6737 5.5125 -1.5176 5.6711
NCI-H650 GDSC2 1.7107 3.7381 -0.7091 1.3472
NCI-H2803 GDSC2 1.7151 5.67 -1.565 5.8641
EMC-BAC-2 GDSC2 1.7314 9.0123 -3.1574 14.5235
NCI-H1048 GDSC2 1.7335 3.6945 -0.6804 1.2
NCI-H1734 GDSC2 1.7456 3.9462 -0.7782 1.6206
KNS-62 GDSC2 1.7486 9.7288 -3.4953 16.1147
SBC-3 GDSC2 1.7566 3.6773 -0.6626 1.1034
NCI-H1703 GDSC2 1.7683 6.6374 -1.9859 8.1551
NCI-H209 GDSC2 1.7969 3.7936 -0.6907 1.1822
COLO 668 GDSC2 1.8026 4.8764 -1.1503 3.415
NCI-H2591 GDSC2 1.8099 12.1061 -4.6189 20.7207
VMRC-LCD GDSC2 1.814 6.0362 -1.6735 6.2953
NCI-H1770 GDSC2 1.8205 3.669 -0.6301 0.9179
NCI-H1105 GDSC2 1.8241 3.8223 -0.6896 1.1523
NCI-H1694 GDSC2 1.8287 3.4301 -0.5343 0.572
NCI-H2731 GDSC2 1.8296 7.7288 -2.4665 10.699
DMS 114 GDSC2 1.8704 5.1804 -1.2474 3.8308
NCI-H1688 GDSC2 1.8906 3.82 -0.6582 0.9682
NCI-H1341 GDSC2 1.8927 6.0356 -1.6242 5.8727
NCI-H1437 GDSC2 1.9226 3.7445 -0.6146 0.781
NCI-H520 GDSC2 1.9401 6.0794 -1.6153 5.7382
NCI-H2342 GDSC2 1.9886 5.1777 -1.1796 3.2937
Lu-135 GDSC2 2.0381 3.8485 -0.6051 0.6691
SBC-1 GDSC2 2.0676 30.0997 -13.3634 36.6827
ABC-1 GDSC2 2.0679 5.0347 -1.0745 2.6502
NCI-H290 GDSC2 2.0961 11.3989 -4.061 17.8289
NCI-H596 GDSC2 2.1909 3.7755 -0.517 0.3389
LCLC-97TM1 GDSC2 2.2065 4.1534 -0.6502 0.7081
DMS 79 GDSC2 2.2203 3.8406 -0.5291 0.3557
DMS 273 GDSC2 2.2405 4.4175 -0.7371 0.9856
NCI-H1650 GDSC2 2.2705 13.2499 -4.8411 20.4922
NCI-H835 GDSC2 2.3488 13.2483 -4.7833 20.1075
RERF-LC-MS GDSC2 2.3667 7.1797 -1.8617 6.3456
NCI-H1355 GDSC2 2.4645 5.2423 -0.9632 1.6878
HOP-92 GDSC2 2.5091 5.0682 -0.8729 1.2822
NCI-H524 GDSC2 2.647 4.3814 -0.5608 0.2723
EBC-1 GDSC2 2.6916 14.5719 -5.1827 20.7817
NCI-H23 GDSC2 2.7179 4.8274 -0.6934 0.5519
SW1573 GDSC2 2.7504 4.9574 -0.7282 0.6317
ChaGo-K-1 GDSC2 2.8494 12.8824 -4.2489 16.9713
A-549 GDSC2 3.1405 10.661 -2.9958 10.8061
⏷ Show the Full List of 182 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 0.4519 2.5303 -0.9111 4.5801
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OE19 GDSC2 -4.2218 1.801 -5.1997 44.5164
TE-4 GDSC2 -2.4101 0.7216 -2.8574 26.5339
TE-6 GDSC2 -1.4321 4.1883 -3.3813 25.0733
EC-GI-10 GDSC2 -1.3791 2.2499 -2.411 19.7214
KYSE-520 GDSC2 -1.1194 4.3356 -3.1592 22.8173
KYSE-450 GDSC2 -0.3376 3.9167 -2.2464 15.1016
OE21 GDSC2 -0.1826 8.2152 -4.2607 24.6548
T.T GDSC2 0.0306 4.7917 -2.3704 14.7044
TE-11 GDSC2 0.1287 1.9129 -0.8514 5.0283
KYSE-140 GDSC2 0.3086 4.631 -2.0636 12.0893
KYSE-270 GDSC2 0.4635 5.6295 -2.4384 13.8648
TE-10 GDSC2 0.7198 3.5799 -1.2314 5.9325
KYSE-410 GDSC2 0.7542 11.1753 -4.9722 24.6326
TE-1 GDSC2 0.9909 6.1934 -2.3147 11.783
KYSE-150 GDSC2 1.0684 7.2731 -2.7891 14.2219
TE-5 GDSC2 1.2413 4.2504 -1.2012 4.6593
COLO 680N GDSC2 1.2885 6.9768 -2.4815 12.0042
OE33 GDSC2 1.4922 5.7967 -1.769 7.4759
KYSE-180 GDSC2 1.5464 7.2701 -2.4409 11.1826
TE-9 GDSC2 1.5699 6.3446 -1.9786 8.5234
TE-8 GDSC2 1.6139 4.8596 -1.2529 4.2812
KYSE-510 GDSC2 2.4001 8.3834 -2.4001 9.1806
KYSE-70 GDSC2 3.8567 13.2978 -3.7752 13.0457
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IGROV-1 GDSC2 -1.1988 3.6475 -2.8988 21.7526
A2780 GDSC2 -0.2647 3.5008 -1.9756 13.2405
JHOS-4 GDSC2 0.2295 7.4687 -3.5448 20.3204
RMG-I GDSC2 0.2377 5.4317 -2.5204 14.9655
EFO-27 GDSC2 0.3209 6.6049 -3.039 17.5523
TOV-21G GDSC2 0.4524 2.0595 -0.6814 3.1631
OVKATE GDSC2 0.9004 5.5159 -2.0482 10.4547
OVTOKO GDSC2 0.9613 4.8248 -1.6657 8.0231
OVCAR-5 GDSC2 0.9934 2.8293 -0.6976 2.2293
OAW42 GDSC2 1.0754 2.8479 -0.6591 1.8946
EFO-21 GDSC2 1.1573 9.9007 -4.022 19.9243
Caov-4 GDSC2 1.1663 5.351 -1.7769 8.2228
FU-OV-1 GDSC2 1.2128 6.6204 -2.362 11.5145
ES-2 GDSC2 1.3127 3.0583 -0.6233 1.3975
OV56 GDSC2 1.3352 2.6542 -0.4477 0.6186
TOV-112D GDSC2 1.3356 5.0287 -1.5074 6.2673
OVCAR-3 GDSC2 1.463 5.5312 -1.662 6.9131
DOV13 GDSC2 1.5881 3.5903 -0.7081 1.475
OVCAR-8 GDSC2 1.7032 6.8586 -2.1348 9.1303
SK-OV-3 GDSC2 1.7154 8.4769 -2.9079 13.2961
Caov-3 GDSC2 1.7498 3.4143 -0.5618 0.7196
Kuramochi GDSC2 1.9468 5.3233 -1.2677 3.821
OC 314 GDSC2 2.1634 8.46 -2.5913 10.6654
OVISE GDSC2 2.1723 11.4076 -4.0104 17.4431
TYK-nu GDSC2 2.189 12.9152 -4.7366 20.2909
OV-90 GDSC2 2.8731 4.3549 -0.4722 0.0949
OAW28 GDSC2 2.9092 11.6594 -3.6197 14.1662
OVCAR-4 GDSC2 3.2266 12.9106 -4.0046 15.2029
JHOS-2 GDSC2 3.4736 15.749 -5.2012 19.2552
OVK18 GDSC2 3.568 14.3097 -4.4442 16.3124
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MIA PaCa-2 GDSC2 0.7684 2.612 -0.7346 2.8341
CFPAC-1 GDSC2 0.7748 4.3296 -1.558 7.8061
SU.86.86 GDSC2 0.9865 2.8644 -0.7175 2.3503
HPAF-II GDSC2 0.9901 3.4478 -0.9851 3.877
QGP-1 GDSC2 0.9917 3.636 -1.0728 4.3911
Panc 04.03 GDSC2 1.0609 5.2518 -1.8029 8.6159
HuP-T3 GDSC2 1.0677 4.7854 -1.5719 7.2184
Capan-1 GDSC2 1.1013 3.3146 -0.8543 2.9214
DAN-G GDSC2 1.1021 3.9777 -1.1624 4.7018
Capan-2 GDSC2 1.2659 8.8072 -3.3982 16.8222
YAPC GDSC2 1.2674 3.8995 -1.0221 3.5812
KP-2 GDSC2 1.3108 2.6239 -0.4467 0.6342
Panc 10.05 GDSC2 1.3165 4.7659 -1.3954 5.6485
Panc 02.03 GDSC2 1.3246 5.7061 -1.8389 8.2391
SUIT-2 GDSC2 1.3349 3.1498 -0.6508 1.5022
Panc 03.27 GDSC2 1.3568 6.7318 -2.3131 10.9014
PaTu 8988t GDSC2 1.3978 7.749 -2.7803 13.3685
BxPC-3 GDSC2 1.429 6.4674 -2.1341 9.72
HuP-T4 GDSC2 1.5137 4.495 -1.1464 3.8565
PL4 GDSC2 1.6626 3.5097 -0.6389 1.0933
SW1990 GDSC2 1.6669 5.4685 -1.5014 5.591
PaTu 8902 GDSC2 1.7071 7.9963 -2.6803 12.1206
Hs 766T GDSC2 1.7107 8.9316 -3.1328 14.4492
Panc 08.13 GDSC2 1.7296 3.8626 -0.7513 1.5157
HPAC GDSC2 1.7776 6.5632 -1.9447 7.903
PSN1 GDSC2 1.957 6.0935 -1.6114 5.6869
AsPC-1 GDSC2 1.9691 9.8224 -3.3826 15.0747
KP-4 GDSC2 2.1391 3.5648 -0.4617 0.2367
MZ-PC-1 GDSC2 2.1603 5.8536 -1.3828 4.1066
KP-3 GDSC2 2.1732 4.4386 -0.7755 1.1864
KP-1N GDSC2 2.538 4.6456 -0.6983 0.6596
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2 0.7587 4.4233 -1.6156 8.1967
NCI-H2452 GDSC2 1.0917 3.5335 -0.961 3.5464
IST-Mes1 GDSC2 1.1725 3.8784 -1.0709 4.0317
NCI-H28 GDSC2 1.186 3.9212 -1.0824 4.0733
MPP 89 GDSC2 1.5465 9.1129 -3.3407 15.8576
NCI-H2052 GDSC2 1.8771 8.4005 -2.7575 12.1506
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 0.2545 6.0902 -2.8357 16.6654
NCI-H660 GDSC2 1.0229 2.8177 -0.6753 2.061
VCaP GDSC2 1.5391 3.4797 -0.6863 1.4298
DU145 GDSC2 1.7233 5.5686 -1.5127 5.5522
22Rv1 GDSC2 1.8467 4.4315 -0.9319 2.2312
PC-3 GDSC2 2.2834 6.3129 -1.5178 4.6332
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 1.5678 4.7134 -1.2137 4.1409
Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHL-1 GDSC2 -0.35 3.5017 -2.0505 13.9646
A-388 GDSC2 -0.0844 4.0957 -2.1186 13.5555
A-431 GDSC2 0.046 5.414 -2.6688 16.3601
SK-MEL-28 GDSC2 0.3633 16.4724 -7.9354 33.1066
HMV-II GDSC2 0.5332 3.3917 -1.2746 6.642
DJM-1 GDSC2 0.6439 4.2696 -1.6248 8.5337
UACC-62 GDSC2 0.7105 3.7011 -1.297 6.357
SK-MEL-2 GDSC2 0.7159 2.0927 -0.5271 1.7413
CP50-MEL-B GDSC2 0.761 3.5211 -1.1738 5.4867
A2058 GDSC2 0.7905 3.0998 -0.9509 4.0726
WM115 GDSC2 0.8878 3.0005 -0.8407 3.2272
COLO 783 GDSC2 0.8893 3.0211 -0.8493 3.2747
SK-MEL-3 GDSC2 0.9003 5.1599 -1.8735 9.416
SK-MEL-24 GDSC2 0.9222 3.3141 -0.9659 3.8963
SK-MEL-30 GDSC2 0.936 2.5917 -0.624 1.9185
Mel Ho GDSC2 0.9384 3.3489 -0.9719 3.8994
WM793 GDSC2 0.9645 3.8931 -1.2132 5.2848
MZ-MEL-7 GDSC2 0.9859 2.7043 -0.6458 1.9587
G-361 GDSC2 1.0383 3.3577 -0.9126 3.3651
M14 GDSC2 1.0515 3.6478 -1.0397 4.0789
WM1552C GDSC2 1.1221 3.0797 -0.7358 2.2335
Mel JuSo GDSC2 1.1558 4.3771 -1.3165 5.5054
SK-MEL-5 GDSC2 1.1603 5.8328 -2.0151 9.6406
COLO 829 GDSC2 1.1658 4.518 -1.3769 5.8437
RPMI-7951 GDSC2 1.1941 2.8959 -0.6156 1.5074
IGR-37 GDSC2 1.2318 2.8641 -0.5825 1.2998
UACC-257 GDSC2 1.2332 3.1111 -0.6878 1.8188
IPC-298 GDSC2 1.243 5.1748 -1.6391 7.2381
MZ-MEL-2 GDSC2 1.2474 8.0865 -3.0566 15.1742
CP66-MEL GDSC2 1.2684 3.5175 -0.8479 2.6124
Hs 938.T GDSC2 1.2871 4.9352 -1.495 6.2933
Hs 940.T GDSC2 1.2956 6.952 -2.4643 11.8916
WM278 GDSC2 1.3215 9.0219 -3.4625 16.9907
WT2-iPS GDSC2 1.3718 5.2484 -1.5878 6.6661
MeWo GDSC2 1.4181 4.2492 -1.0914 3.7116
WM35 GDSC2 1.4401 4.6649 -1.2695 4.6826
VMRC-MELG GDSC2 1.4543 3.3034 -0.6549 1.3808
LOX-IMVI GDSC2 1.4608 3.3943 -0.6899 1.5371
LB373-MEL-D GDSC2 1.4799 2.8532 -0.4618 0.5616
GAK GDSC2 1.4885 3.1321 -0.568 0.962
IGR-1 GDSC2 1.5319 5.3716 -1.5417 6.0779
LB2518-MEL GDSC2 1.5677 2.9426 -0.4588 0.493
SK-MEL-1 GDSC2 1.781 3.0944 -0.4293 0.2974
A101D GDSC2 1.7927 3.0626 -0.4135 0.2551
MMAc-SF GDSC2 1.7945 8.1953 -2.7157 12.1131
A-375 GDSC2 1.7977 7.1235 -2.1979 9.2863
G-mel GDSC2 1.8104 3.5355 -0.5824 0.7485
IST-MEL1 GDSC2 1.8146 5.9288 -1.6232 6.0095
COLO 800 GDSC2 1.9255 3.9362 -0.6885 1.0568
451Lu GDSC2 1.9656 4.407 -0.8611 1.7553
SH-4 GDSC2 2.0307 4.1933 -0.7428 1.1812
COLO 679 GDSC2 2.1272 3.7736 -0.541 0.4274
RVH-421 GDSC2 2.145 9.173 -2.9454 12.5376
COLO 792 GDSC2 2.1952 4.1403 -0.6499 0.7145
HT-144 GDSC2 2.6913 4.8524 -0.7131 0.6199
SK-MEL-31 GDSC2 3.7459 15.4861 -4.8874 17.6301
EquiPSC Line K2 GDSC2 2.6195 4.9861 -0.7929 0.91
⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 1.3738 9.5558 -3.6869 17.9034
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE 441.T GDSC2 0.38 2.1852 -0.7943 4.0263
GCT GDSC2 0.6172 3.1703 -1.1048 5.3906
KYM-1 GDSC2 0.6646 2.8176 -0.9008 4.0357
STS-0421 GDSC2 0.9461 3.0328 -0.8192 2.995
Rh30 GDSC2 0.9533 4.9737 -1.7441 8.5135
Rh41 GDSC2 0.9626 4.9094 -1.706 8.2628
Hs 633.T GDSC2 1.0728 4.42 -1.3925 6.1316
MES-SA GDSC2 1.1067 4.4918 -1.404 6.1285
EW-8 GDSC2 1.113 3.2537 -0.8195 2.7074
VA-ES-BJ GDSC2 1.1575 4.9294 -1.5795 7.0677
G-401 GDSC2 1.3205 7.9868 -2.9535 14.4644
HT-1080 GDSC2 1.4623 3.1024 -0.5682 0.9879
RKN GDSC2 1.5247 5.8371 -1.7666 7.3948
G-402 GDSC2 1.5898 6.1475 -1.8711 7.8649
SW982 GDSC2 1.6752 3.3826 -0.5824 0.8547
RD GDSC2 1.7545 6.1877 -1.7824 7.0268
MFH-ino GDSC2 1.7821 6.1412 -1.7429 6.7487
SW684 GDSC2 1.7978 3.1574 -0.4456 0.3309
SK-LMS-1 GDSC2 1.8083 4.0505 -0.7905 1.6073
SK-UT-1 GDSC2 2.5739 4.4638 -0.6175 0.4225
SW872 GDSC2 2.6509 11.7003 -3.8154 15.5635
A-204 GDSC2 2.6798 9.7171 -2.8479 10.9519
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-N87 GDSC2 -4.9231 1.7687 -5.9417 49.5981
SK-GT-2 GDSC2 -4.6213 -2.1079 -4.6609 46.4686
NUGC-3 GDSC2 0.3078 7.6551 -3.5742 20.2309
ECC10 GDSC2 0.4101 2.7987 -1.074 5.6961
SNU-16 GDSC2 0.5349 2.3744 -0.7764 3.5608
ECC12 GDSC2 0.5793 3.1111 -1.1032 5.469
HSC-39 GDSC2 0.5893 3.6814 -1.3756 7.1312
MKN1 GDSC2 0.655 3.5865 -1.281 6.3883
Fu97 GDSC2 0.8175 4.8448 -1.7795 9.05
TMK-1 GDSC2 1.0099 7.83 -3.1085 16.0388
SCH GDSC2 1.0275 3.2605 -0.8743 3.1645
TGBC11TKB GDSC2 1.031 5.8081 -2.096 10.419
HGC-27 GDSC2 1.1064 4.157 -1.2446 5.1792
RF-48 GDSC2 1.1617 3.0676 -0.7081 2.0259
GCIY GDSC2 1.164 6.4822 -2.3296 11.4475
KATO III GDSC2 1.2234 3.7913 -0.9991 3.5281
IM95 GDSC2 1.2461 5.0702 -1.5868 6.9216
NUGC-4 GDSC2 1.2467 9.8141 -3.9107 19.2175
MKN28 GDSC2 1.4521 7.0733 -2.4117 11.2354
23132/87 GDSC2 1.4536 8.6024 -3.1581 15.1833
AGS GDSC2 1.569 7.7081 -2.6377 12.2052
MKN45 GDSC2 1.641 2.7853 -0.372 0.219
RERF-GC-1B GDSC2 1.9651 5.3422 -1.2657 3.7822
OCUM-1 GDSC2 2.0485 4.5349 -0.8733 1.7203
SNU-5 GDSC2 2.2534 3.7975 -0.5012 0.28
SNU-1 GDSC2 2.6642 4.4486 -0.578 0.3009
Hs 746.T GDSC2 2.7767 9.7972 -2.8229 10.6397
MKN7 GDSC2 3.0252 16.001 -5.6409 21.5924
SNG-M GDSC2 1.1888 3.0106 -0.6681 1.779
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-62 GDSC2 0.9053 3.9574 -1.2845 5.8414
IHH-4 GDSC2 0.906 4.0379 -1.3229 6.0724
TT GDSC2 0.9079 2.8874 -0.7755 2.8131
ML-1 [Human leukemia] GDSC2 0.9309 3.6235 -1.107 4.7183
BHT-101 GDSC2 1.0212 2.6801 -0.6151 1.7425
8305C GDSC2 1.0468 12.8839 -5.5917 25.8916
K5 GDSC2 1.1292 3.4683 -0.9079 3.1757
ASH-3 GDSC2 1.3458 3.2755 -0.6988 1.7237
HTC-C3 GDSC2 1.4369 5.1243 -1.4864 5.9428
CGTH-W-1 GDSC2 1.5014 3.8688 -0.8729 2.3972
B-CPAP GDSC2 1.511 3.1306 -0.5569 0.8959
FTC-133 GDSC2 1.657 8.2634 -2.8454 13.1055
TT2609-C02 GDSC2 1.8027 4.2832 -0.8914 2.0892
KMH-2 GDSC2 1.993 4.0683 -0.7103 1.0846
8505C GDSC2 2.2079 4.5826 -0.817 1.3221
WRO GDSC2 2.4374 4.6104 -0.7267 0.8101
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHU-022 GDSC2 -1.9587 3.4449 -3.5396 27.9073
SAT [Human HNSCC] GDSC2 -1.8828 5.5009 -4.4427 31.2136
DOK GDSC2 -1.7691 2.4779 -2.9061 24.0076
BB30-HNC GDSC2 -1.3735 3.9559 -3.2135 24.0311
PCI-15A GDSC2 -1.0072 1.8135 -1.8397 14.9382
HO-1-u-1 GDSC2 -0.9872 1.9621 -1.8895 15.1641
FaDu GDSC2 -0.796 3.6913 -2.5448 18.3572
Ca9-22 GDSC2 -0.6034 2.6501 -1.8563 13.6074
JHU-029 GDSC2 -0.3357 1.5574 -1.0735 7.8399
HSC-3 GDSC2 -0.3141 4.7655 -2.6493 17.356
PCI-06A GDSC2 -0.1181 3.616 -1.9073 12.3719
NCI-H3118 GDSC2 0.0382 4.7379 -2.3372 14.4881
CAL-27 GDSC2 0.156 4.3038 -2.0233 12.2754
KOSC-2 GDSC2 0.2075 2.807 -1.2345 7.2315
HO-1-N-1 GDSC2 0.2218 2.1907 -0.9165 5.1889
UPCI-SCC-090 GDSC2 0.2375 3.6102 -1.6112 9.5113
CAL-33 GDSC2 0.3054 3.4213 -1.4633 8.4041
HSC-2 GDSC2 0.3227 3.218 -1.3486 7.6403
JHU-011 GDSC2 0.3236 5.8669 -2.6683 15.5516
HSC-4 GDSC2 0.3741 4.2739 -1.8337 10.5145
OSC-19 GDSC2 0.411 5.7219 -2.5261 14.5091
SCC-9 GDSC2 0.438 5.0722 -2.181 12.4346
SAS GDSC2 0.5116 3.9553 -1.5691 8.5236
OSC-20 GDSC2 0.589 3.841 -1.4545 7.6198
BICR 78 GDSC2 0.6458 5.3687 -2.1669 11.7989
BICR 22 GDSC2 0.657 3.0318 -1.0094 4.714
SCC-25 GDSC2 0.6683 2.9547 -0.9643 4.4137
BHY GDSC2 0.735 4.7291 -1.7834 9.2756
Detroit 562 GDSC2 0.7552 5.7597 -2.2773 12.161
BB49-HNC GDSC2 0.7556 6.145 -2.4677 13.2516
SCC-4 GDSC2 0.8474 4.8338 -1.7522 8.8128
SCC-15 GDSC2 0.896 6.3625 -2.4689 12.8969
PCI-04B GDSC2 0.9337 6.3152 -2.4173 12.5102
KON GDSC2 1.0096 10.2148 -4.2923 21.4241
PE/CA-PJ15 GDSC2 1.2691 5.1184 -1.5945 6.9184
LB771-HNC GDSC2 1.4342 7.2654 -2.518 11.8642
BICR 31 GDSC2 1.6937 6.4967 -1.9684 8.2075
BICR 10 GDSC2 1.7399 4.4905 -1.0146 2.793
SKN-3 GDSC2 1.7574 6.1684 -1.7714 6.9584
PCI-30 GDSC2 2.1139 10.7457 -3.7292 16.3482
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-29 GDSC2 0.5653 4.4834 -1.7898 9.7427
5637 GDSC2 0.8795 5.023 -1.8216 9.1541
BFTC-905 GDSC2 0.8811 2.624 -0.6708 2.2662
639V GDSC2 1.0322 8.8844 -3.6141 18.436
TCCSUP GDSC2 1.2518 3.0413 -0.6477 1.5921
KU-19-19 GDSC2 1.2979 2.928 -0.5761 1.1934
SW1710 GDSC2 1.3165 3.3889 -0.7638 2.094
HT-1376 GDSC2 1.3884 7.6732 -2.7501 13.2299
RT-112 GDSC2 1.4159 4.0753 -1.0135 3.2823
SW780 GDSC2 1.4553 7.2951 -2.5173 11.8117
T24 GDSC2 1.685 4.1323 -0.8884 2.225
UM-UC-3 GDSC2 1.8944 3.6947 -0.6076 0.7767
647V GDSC2 1.9766 8.6843 -2.8256 12.2881
J82 GDSC2 2.0939 6.721 -1.8171 6.5836
HT-1197 GDSC2 2.0981 9.8187 -3.2898 14.3422
RT-4 GDSC2 2.2045 10.6208 -3.6042 15.5819
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-39 GDSC2 -2.28 0.2844 -2.5713 24.4166
DSH1 GDSC2 -1.8565 3.2327 -3.3398 26.5537
OVCA420 GDSC2 -1.7216 4.1101 -3.621 27.3095
BPH-1 GDSC2 -1.4536 5.3388 -3.9601 27.7295
OVMIU GDSC2 -0.213 5.2666 -2.8129 17.9423
ME-180 GDSC2 -0.1102 5.151 -2.6679 16.8256
C-33 A GDSC2 0.1613 3.9812 -1.8578 11.2509
C-4-I GDSC2 0.1891 3.0042 -1.3476 7.9936
JEG-3 GDSC2 0.4008 5.258 -2.3029 13.2534
SKG-IIIa GDSC2 0.4692 3.5706 -1.4109 7.6497
TC-YIK GDSC2 0.5518 2.5219 -0.836 3.8877
OV17R GDSC2 0.5901 3.9371 -1.501 7.9048
NT2-D1 GDSC2 0.6374 3.5927 -1.2968 6.5275
NCC-IT GDSC2 0.793 4.6691 -1.7112 8.6955
SW954 GDSC2 0.7986 2.952 -0.8753 3.6046
OMC-1 [Human cervical carcinoma] GDSC2 0.8871 4.6281 -1.6229 7.936
DoTc2 4510 GDSC2 0.9149 4.2499 -1.4192 6.637
UWB1.289 GDSC2 0.9367 7.2186 -2.8615 14.9435
Ca Ski GDSC2 1.0007 8.2673 -3.3322 17.178
PA-1 GDSC2 1.1368 3.7404 -1.029 3.8556
SW756 GDSC2 1.159 5.0174 -1.6208 7.3104
KGN GDSC2 1.1798 9.9079 -4.0083 19.8084
PWR-1E GDSC2 1.193 3.6348 -0.9457 3.2787
HeLa GDSC2 1.2152 2.3888 -0.397 0.5243
JAR GDSC2 1.3412 4.9161 -1.4503 5.9211
SW962 GDSC2 1.4139 8.2531 -3.0157 14.5585
PEO1 GDSC2 1.465 4.8951 -1.361 5.1623
HEC-1 GDSC2 1.5312 3.0673 -0.5226 0.7441
JHOS-3 GDSC2 1.5369 9.919 -3.7442 17.7626
SiHa GDSC2 1.7505 3.6917 -0.6713 1.1451
HEY GDSC2 1.8711 4.2175 -0.829 1.7134
LB831-BLC GDSC2 1.9095 4.0018 -0.7221 1.2069
NEC8 GDSC2 1.9519 3.5399 -0.5248 0.4714
ACC-OV7 GDSC2 2.0558 5.3644 -1.2246 3.4307
SKN GDSC2 2.2037 4.546 -0.8043 1.2745
OVCA433 GDSC2 2.3627 11.6176 -3.9769 16.879
MS751 GDSC2 2.4587 16.0123 -6.0609 24.0375
SiSo GDSC2 2.5728 4.4884 -0.6268 0.4459
HT-3 GDSC2 3.0762 14.3502 -4.8012 18.6324
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Osimertinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Brigatinib DM7W94S Moderate Decreased metabolism of Osimertinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [11]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Osimertinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
PF-06463922 DMKM7EW Moderate Increased metabolism of Osimertinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [13]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Osimertinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Osimertinib and Selpercatinib. Lung cancer [2C25] [11]
Coadministration of a Drug Treating the Disease Different from Osimertinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Osimertinib and Ivosidenib. Acute myeloid leukaemia [2A60] [15]
Arn-509 DMT81LZ Major Increased metabolism of Osimertinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Osimertinib and Gilteritinib. Acute myeloid leukaemia [2A60] [13]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Osimertinib and Oliceridine. Acute pain [MG31] [17]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Osimertinib and Levalbuterol. Asthma [CA23] [18]
Troleandomycin DMUZNIG Major Decreased metabolism of Osimertinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [13]
Ag-221 DMS0ZBI Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [16]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Osimertinib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [13]
Talazoparib DM1KS78 Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [19]
LY2835219 DM93VBZ Moderate Decreased metabolism of Osimertinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Tucatinib DMBESUA Major Decreased metabolism of Osimertinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Osimertinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [13]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Osimertinib and Osilodrostat. Cushing syndrome [5A70] [13]
MK-8228 DMOB58Q Moderate Decreased metabolism of Osimertinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [13]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Osimertinib and Deutetrabenazine. Dystonic disorder [8A02] [13]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Osimertinib and Ingrezza. Dystonic disorder [8A02] [13]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Osimertinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Osimertinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [11]
Tazemetostat DMWP1BH Moderate Increased metabolism of Osimertinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [13]
Ripretinib DM958QB Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [16]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Osimertinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [13]
Berotralstat DMWA2DZ Major Decreased clearance of Osimertinib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [20]
IPI-145 DMWA24P Moderate Decreased metabolism of Osimertinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [13]
Arry-162 DM1P6FR Moderate Increased metabolism of Osimertinib caused by Arry-162 mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Osimertinib and LGX818. Melanoma [2C30] [13]
Rimegepant DMHOAUG Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Rimegepant. Migraine [8A80] [21]
Lasmiditan DMXLVDT Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [22]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Osimertinib and Siponimod. Multiple sclerosis [8A40] [16]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Osimertinib and Ocrelizumab. Multiple sclerosis [8A40] [23]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Osimertinib and Ozanimod. Multiple sclerosis [8A40] [11]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Osimertinib and Entrectinib. Non-small cell lung cancer [2C25] [13]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Osimertinib and Rucaparib. Ovarian cancer [2C73] [13]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Osimertinib and Triclabendazole. Parasitic worm infestation [1F90] [13]
Abametapir DM2RX0I Moderate Decreased metabolism of Osimertinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [24]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Osimertinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [25]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Osimertinib and Lefamulin. Pneumonia [CA40] [26]
Relugolix DMK7IWL Major Decreased clearance of Osimertinib due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [27]
Darolutamide DMV7YFT Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [28]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Osimertinib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [29]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Osimertinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [13]
Tedizolid DMG2SKR Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [11]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Osimertinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [11]
Larotrectinib DM26CQR Moderate Increased metabolism of Osimertinib caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [13]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Osimertinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [13]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Osimertinib and Pitolisant. Somnolence [MG42] [13]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Osimertinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [30]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Osimertinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [31]
Elagolix DMB2C0E Moderate Increased metabolism of Osimertinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [13]
⏷ Show the Full List of 48 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium stearyl fumarate E00545 23665634 lubricant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Haematite red E00236 14833 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Osimertinib 40 mg tablet 40 mg Oral Tablet Oral
Osimertinib 80 mg tablet 80 mg Oral Tablet Oral
Osimertinib Mesylate eq 40mg base tablet eq 40mg base Tablet Oral
Osimertinib Mesylate eq 80mg base tablet eq 80mg base Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
5 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
6 Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
7 Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2017 Apr 15;321:18-26. doi: 10.1016/j.taap.2017.02.017. Epub 2017 Feb 22.
8 Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochem Pharmacol. 2022 Jan;195:114864. doi: 10.1016/j.bcp.2021.114864. Epub 2021 Nov 30.
9 Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.
10 AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. J Cell Biochem. 2019 Jan;120(1):756-767. doi: 10.1002/jcb.27434. Epub 2018 Aug 26.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
13 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
14 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
15 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
18 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
19 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
20 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
21 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
22 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
23 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
24 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
25 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
26 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
27 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
28 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
29 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
30 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
31 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".